Pfizer and BioNTech commenced global clinical trial to evaluate COVID-19 vaccine in pregnant women
On Feb. 18, 2021, Pfizer and BioNTech announced that the first participants hadbeen dosed in a global Phase…
On Feb. 18, 2021, Pfizer and BioNTech announced that the first participants hadbeen dosed in a global Phase…
On Feb. 17, 2021, BioNTech announced an agreement with the European Commission (EC) to supply an additional 200…
On Feb. 17, 2021, BioNTech announced results from an in vitro study that provided additional data on the…
On Feb. 16, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, has submitted a conditional Marketing Authorisation…
On Feb. 15, 2021, the WHO listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use, giving…
On Feb. 15, 2021, Novavax and SK Bioscience announced an expanded collaboration and license agreement. In addition to…
On Feb. 13, 2021, the University of Oxford, together with three partner sites in London, Southampton and Bristol,…
On Feb. 12, 2021, CureVac announced initiation of a rolling submission with the European Medicines Agency (EMA) for…
On Feb. 12, 2021, the NIH announced that enrollment had begun to test additional investigational drugs in the…
On Feb. 12, 2021, Moderna announced that the Canadian Government had increased its confirmed order commitment by 4…
On Feb. 12, 2021, BioNTech announced that the U.S. government had exercised its option for an additional 100…
On Feb. 11, 2021, Moderna announced that the U.S. government had purchased an additional 100 million doses of…
On Feb. 10, 2021, BioNTech announced they had increased their manufacturing capacity in Marburg, Germany to up to…
On Feb. 8, 2021, Repligen and Navigo Proteins announced that they had completed the development and initiated the…
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
On Feb. 7, 2021, Oxford University announced that an analysis, submitted as a pre-print prior to peer-review publication,…
On Feb. 5, 2021, CureVac announced that it had entered a collaboration with the UK Government to develop…
On Feb. 5, 2021, Oxford University announced that a preprint of ongoing work to assess effectiveness of Oxfordï¾’s…
On Feb. 4, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
On Feb. 4, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, had submitted an application to the…
On Feb. 3, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
On Feb. 3, 2021, Vaxart announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its…
On Feb. 3, 2021, Dynavax Technologies and Serum Institute of India announced that the first participant has been…
On Feb. 3, 2021, IAVI and Scripps Research announced a phase 1 clinical trial testing a novel vaccine…
On Feb. 3, 2021, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 7.5…
On Feb. 3, 2021, Moderna announced that the Singapore Health Sciences Authority (HSA) had approved the interim authorization…
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
On Feb. 2, 2021, GlaxoSmithKline and CureVac announced a new ï¾€150m collaboration, building on their existing relationship, to…
On Feb. 2, 2021, Novavax announced a memorandum of understanding with the Canadian government to produce NVX-CoV2373, the…